Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203631 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT01203631 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 78 participants.
The verdict
NCT01203631, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and North America. The aim of the trial is to assess disease activity and safety in subjects with moderately to severely active Crohn's disease (CD) when treated with NNC 0142-0000-0002.
Interventions
- DRUG Placebo
- DRUG NNC 0142-0000-0002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01203631
The ClinicalTrials.gov registry entry for NCT01203631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01203631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01203631 about?
NCT01203631 is a clinical study titled "Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease". This trial is conducted in Europe and North America. The aim of the trial is to assess disease activity and safety in subjects with moderately to severely active Crohn's disease (CD) when treated with NNC 0142-0000-0002.
What is the current status of trial NCT01203631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2011-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01203631?
The interventions under investigation include: Placebo (DRUG), NNC 0142-0000-0002 (DRUG).
Who is sponsoring clinical trial NCT01203631?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.